Want to see AKTX full AI Analyst Report?
Top Page
Akari Therapeutics
(NASDAQ:AKTX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$8.00
▲(1.65% Upside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by weak financial performance (no revenue, widening TTM losses, and persistent cash burn with declining equity), which elevates funding and dilution risk. Technicals are comparatively better with price above major moving averages, but mixed momentum (slightly negative MACD) tempers the signal. Valuation provides limited support because the negative P/E reflects ongoing losses and there is no dividend yield.
Positive Factors
Low Leverage
Very low leverage limits fixed financial obligations and reduces the risk that interest costs constrain development spending. This gives Akari greater balance-sheet flexibility than a highly indebted biotech, although it does not eliminate the need for future external financing.
Negative Factors
No Revenue and Widening Losses
The absence of revenue leaves Akari dependent on successful clinical development before it can establish operating income. Widening losses indicate increasing pressure on earnings power and suggest that the company may need substantial additional capital to sustain its development activities.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage limits fixed financial obligations and reduces the risk that interest costs constrain development spending. This gives Akari greater balance-sheet flexibility than a highly indebted biotech, although it does not eliminate the need for future external financing.
Read all positive factors
Akari Therapeutics (AKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.26M
Dividend YieldN/A
Average Volume (3M)59.66K
Price to Earnings (P/E)―
Beta (1Y)1.54
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1600.00
Shares Outstanding2,285,165
10 Day Avg. Volume52,815
30 Day Avg. Volume59,662
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.35
Forecast
1Y Price Target
$25.50Price Target Upside224.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-10.67
Revenue Forecast (FY)N/A
Akari Therapeutics Business Overview & Revenue Model
Company Description
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell...
Akari Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -31.84M | -17.35M | -19.53M | -10.00M | -17.74M | -17.42M |
| Net Income | -30.96M | -17.30M | -19.79M | -10.01M | -17.75M | -17.42M |
Balance Sheet | ||||||
| Total Assets | 38.62M | 47.89M | 50.56M | 4.36M | 13.83M | 11.65M |
| Cash, Cash Equivalents and Short-Term Investments | 7.69M | 5.20M | 2.60M | 3.85M | 13.25M | 9.36M |
| Total Debt | 693.00K | 754.00K | 3.26M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 20.03M | 19.56M | 28.33M | 4.58M | 12.04M | 6.09M |
| Stockholders Equity | 18.59M | 28.33M | 22.23M | -229.00K | 1.79M | 5.55M |
Cash Flow | ||||||
| Free Cash Flow | -10.74M | -10.57M | -12.55M | -16.43M | -21.50M | -18.85M |
| Operating Cash Flow | -10.74M | -10.57M | -12.55M | -16.43M | -21.50M | -18.85M |
| Investing Cash Flow | -15.00K | 0.00 | 382.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 15.72M | 13.17M | 10.99M | 7.02M | 25.29M | 14.29M |
Akari Therapeutics Technical Analysis
Negative
7.87
Price Trends
9.20
Negative
10.16
Negative
9.15
Negative
Market Momentum
-0.24
Negative
44.55
Neutral
57.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AKTX, the sentiment is Negative. The current price of 7.87 is below the 20-day moving average (MA) of 8.79, below the 50-day MA of 9.20, and below the 200-day MA of 9.15, indicating a bearish trend. The MACD of -0.24 indicates Negative momentum. The RSI at 44.55 is Neutral, neither overbought nor oversold. The STOCH value of 57.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AKTX.
Akari Therapeutics Risk Analysis
Akari Therapeutics disclosed 53 risk factors in its most recent earnings report. Akari Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Akari Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $262.04M | 0.79 | -6.74% | ― | -100.00% | 95.16% | |
46 Neutral | $16.26M | >-0.01 | -147.45% | ― | ― | ― | |
46 Neutral | $38.54M | -3.66 | -91.11% | ― | ― | 35.47% | |
46 Neutral | $11.55M | -0.32 | -218.59% | ― | ― | 38.14% | |
44 Neutral | $6.50M | -0.02 | -816.56% | ― | ― | 85.06% |
* Healthcare Sector Average
AKTX
Akari Therapeutics
8.10
-21.46
-72.60%
NNVC
NanoViricides
1.39
-0.04
-2.87%
MBRX
Moleculin Biotech
5.89
-239.31
-97.60%
PASG
Passage Bio
3.51
-3.92
-52.76%
SABS
SAB Biotherapeutics
3.04
0.12
4.11%
Akari Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Akari Therapeutics Enhances CEO Compensation, Equity Incentives
Neutral
Oct 1, 2026
On September 29, 2026, Akari Therapeutics amended its chief executive officer agreement with CEO Abizer Gaslightwala, retroactive to August 18, 2026, significantly increasing his total compensation package. The amendment raises his annual base sal...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.